Latest Content

Mogenry (sonpiretigene isteparvovec, MC-010) is a gene therapy for retinitis pigmentosa with severe vision loss.

Heru's PretestPro runs 4 pretesting exams in about 90 seconds on the Heru Prime wearable platform and reaches all current and future customers via free software update.

In the first episode of the second season of The Independent Advantage, Diana Canto-Sims, OD, chats with practice owner Maria Sampalis, OD, on why artificial intelligence has boomed in practice ownership spaces.

The latest in drug and technology developments and updates from August 2026.

Merabet, OD, PhD, MPH, discusses what his research on motion processing reveals about the neural roots of CVI and where diagnostic tools like neuroimaging and eye tracking are headed.

Host Hamza Shah, OD, MS, FAAO, is joined by Leonard Messner, OD, to discuss GLP-1s and idiopathic intracranial hypertension, inspired by Mitchell et al's paper, "The Effect of GLP-1RA Exenatide on Idiopathic Intracranial Hypertension: A Randomized Clinical Trial."

Periocular skin treatment is emerging as a complementary treatment for dry eye disease.

Catch up on the top stories in optometry during the week of August 31-September 4.

SightGlass Vision reports the milestone just 1 year after reaching 1 million users.

Acoltremon ophthalmic solution 0.003% usage was associated with improved performance in visual acuity tasks.

The OTC lens is the first FDA-recognized device in its class, targeting light sensitivity in patients with episodic migraine aged 12 and older.

Cerebral visual impairment is now the leading cause of childhood vision loss. Three experts explain the history, science, and clinical signs eye care providers need to know.

The evolution of IPL is not limited to its expanding role in ocular surface disease.